Effect of Postbiotic <i>Bifidobacterium longum</i> CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot StudyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This randomised, parallel, double-blind, placebo-controlled pilot study examined the effect of a heat-treated postbiotic, Bifidobacterium longum CECT 7347 (HT-ES1), in healthy adults with mild to moderate digestive symptoms. Participants received either HT-ES1 or a matching placebo daily for 8 weeks, with an additional follow-up assessment at week 10. The study tracked gastrointestinal symptom scores, gut microbiota composition via 16S rRNA sequencing, biochemical markers, anthropometric parameters, and adverse events.
Who was studied?
A total of 60 healthy adults with mild to moderate digestive symptoms were recruited and randomised to receive either the HT-ES1 postbiotic or an identical placebo. The abstract does not specify further demographic details such as age range or sex distribution. The population was drawn from generally healthy individuals rather than a diagnosed patient cohort.
What were the most important findings?
Gastrointestinal symptoms changed minimally between the two groups, but the HT-ES1 group showed a significant decrease in total and non-HDL cholesterol compared to placebo. The intervention group also had a significant increase in the abundance of Faecalibacterium and Anaerobutyricum, both of which correlated positively with butyrate concentrations. Faecal calprotectin rose significantly over time in the placebo group but stayed stable in the HT-ES1 group.
What are the greatest implications of this study?
The findings suggest that this heat-treated Bifidobacterium longum postbiotic may support cardiometabolic and intestinal health in healthy adults, even without producing marked changes in digestive symptoms. The rise in butyrate-associated, anti-inflammatory commensals such as Faecalibacterium alongside stable calprotectin levels points to a possible gut-barrier or anti-inflammatory benefit. These results support further, larger trials to confirm postbiotic effects on cholesterol and microbiota composition.